CATEGORY

Antisense Oligonucleotides

New modality of therapeutics using DNA technologies.

Beroe LiVE.Ai™

AI-powered self-service platform for all your sourcing decision needs across 1,600+ categories llike Antisense Oligonucleotides.

Market Data, Sourcing & Supplier Intelligence, and Price & Cost Benchmarking.

Schedule a Demo
Meet Abi

The World’s first Digital Market Analyst

    Schedule a Demo
    Meet Abi

    The World’s first Digital Market Analyst

    Abi, the AI-powered digital assistant brings together data, insights, and intelligence for faster answers to sourcing questions

    Antisense Oligonucleotides Suppliers


    Antisense Oligonucleotides Supplier

    Find the right-fit antisense oligonucleotides supplier for your specific business needs and filter by location, industry, category, revenue, certifications, and more on Beroe LiVE.Ai™.

    Sample Supplier
    Company
    IQVIA HOLDINGS INC.
    Location
    Jackson, Mississipi
    Duns number
    3862211

    D&B SER Rating

    dnb logo

    Up to 3 months

    1 9
    4
    Low Risk High Risk

    The Supplier Evaluation Risk (SER) Rating is Dun & Bradstreet’s proprietary scoring system used to assess the probability that a business will seek relief from creditors or cease operations within the next 12 months. SER ratings range from 1 to 9, with 9 indicating the highest risk of failure. We’ve prepared an infographic to help business owners better understand what influences their SER Rating.

    Moody`s ESG Solution
    ESG Profile

    Company and Sector Performance
    36

    100
    Limited (1)
    ESG Perfomance (/100)
    Environment
    41
    Social
    30
    Governance
    43
    6 Domains Performance (/100)
    Business behaviour
    48
    Human rights
    39
    Community Environment
    31
    Corporate governance
    40
    Human resources
    22
    Security Scorecard
    77

    Threat indicators
    C
    75
    Network Security
    Detecting insecure network settings
    A
    100
    Hacker Chatter
    Monitoring hacker sites for chatter about your company
    D
    63
    DNS Health
    Detecting DNS insecure configuration and vulnerabilities
    C
    70
    Application Security
    Detecting common website application vulnerbilities
    C
    77
    Endpoint Security
    Detecting unprotected enpoints or entry points of user tools, such as desktops, laptops mobile devices, and virtual desktops
    A
    100
    Cubic Score
    Proprietary algorithms checking for implementation of common security best practices
    D
    60
    Patching Cadence
    Out of date company assets which may contain vulnerabilities of risk
    A
    100
    Social Engineering
    Measuring company awareness to a social engineering or phising attack
    A
    100
    IP Reputation
    Detecting suspecious activity, such as malware or spam, within your company network
    A
    100
    Information Leak
    Potentially confidential company information which may have been inadvertently leaked

    Industry Comparison
    iqvia.com
    Industry average
    Adverse Media Appearances
    Environmental Issues
    0
    Workforce Health Safety Issues
    0
    Product Service Issues
    1
    Human Rights Issues
    0
    Production Supply Chain Issues
    0
    Environmental Non Compliance Flags
    1
    Corruption Issues
    0
    Regulatory Non Compliance Flags
    2
    Fraud Issues
    0
    Labor Health Safety Flags
    0
    Regulatory Issues
    2
    Workforce Disputes
    0
    Sanctions
    0
    esg energy transition
    28
    Discrimination Workforce Rights Issues
    0
    esg controversies critical severity
    No

    Antisense Oligonucleotides market report transcript


    Global Outlook on Antisense Oligonucleotides 

    The Global Oligonucleotides market is expected to grow at a CAGR of ~10-11 percent during 2016-2021 which is driven by factors such as increased use in clinical and diagnostic applications , increasing R&D funding by pharma and biotech companies and growing grants from governments

    North America holds the largest market size of oligonucleotides manufacturing market owing to established supply base, infrastructure and regional demand . Asia Pac is expected to grow at highest CAGR owing to increase in research on genomics and proteomics and increase in R&D funding.The Global Oligonucleotides market is expected to grow at a CAGR of ~10-11% during 2016-2021 which is driven by factors such as increased use in clinical and diagnostic applications , increasing R&D funding by pharma and biotech companies & growing grants from governments.

    • The Oligo manufacturing market is a very niche with very few players capable of producing commercial scale.
    • Being a technology driven industry, with reputation and experience standing tall for CMO selection, Specialist players (Niche players) are trying to increase the service capabilities by collaborating with Pharma to invest in new technologies.

    Industry Trends

    Increasing R&D

    Changing regulations and pharma increasing focus on developing oligonucleotides in various neurological disorders increased the market for Antisense oligonucleotides. E.g.: Ionis Pharmaceutical is developing either alone or in collaborations with a strategic partner and has 25 percent of the total drugs in pipeline globally.

    Regulatory Environment

    The two largest regulatory bodies in the world, FDA and EU MHRA approved to use Oligonucleotides as drug. Of all the ASO molecules evaluated as of 2017 the regulatory authorities assessed that six has clear clinical benefits in rigorously controlled trials. E.g.: Kynamro, Eteplirsen, Defitelio, Spinraza, Vitravene, Macugen.

    Technology advancements

    New start-up companies with new technologies and rich patent portfolios are aiming to advance entirely new classes of oligo therapeutics. E.g.: Seattle based HaloBio developed multivalent RNA molecules (MV-RNA) for gene targeting. MV-RNA utilizes the same RISC pathway as siRNA, but expands gene targeting, eliminates, sense-strand off-target effects, and introduces the first “junction containing” structures to RNAi.

    Supplier Landscape

    North America holds the largest market size of oligonucleotides manufacturing market owing to established supply base, infrastructure and regional demand . Asia Pac is expected to grow at highest CAGR owing to increase in research on genomics and proteomics and increase in R&D funding. The ASO manufacturing market is highly competitive with the presence of several large players (e.g.: Nitto, Syngene) and emerging players (Manufacturing niche product segments).